Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ivonescimab - Akeso Biopharma/Summit Therapeutics

Next Previous
Drug Profile

Ivonescimab - Akeso Biopharma/Summit Therapeutics

Alternative Names: AK-112; Evoximab; PD-1/VEGF bi-specific antibody - Akeso Biopharma; SMT-112

Latest Information Update: 06 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Akeso Biopharma
  • Developer Akeso Biopharma; Summit Therapeutics
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase III Adenocarcinoma; Biliary cancer; Small cell lung cancer; Squamous cell cancer; Triple negative breast cancer
  • Phase II Colorectal cancer; Gynaecological cancer; Liver cancer; Ovarian cancer
  • Phase I/II Glioblastoma; Solid tumours

Most Recent Events

  • 31 Oct 2025 Summit intends to open clinical trial sites in the United States for the Phase III study in Colorectal cancer by the end of 2025.
  • 20 Oct 2025 Summit Therapeutics plan to submit a BLA application in quarter four of 2025
  • 19 Oct 2025 Efficacy and adverse event data from the phase III HARMONi-6 trial in Non-small cell lung cancer released by Summit Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top